n(1)-methylnicotinamide has been researched along with Hypertension in 2 studies
N(1)-methylnicotinamide: RN given refers to parent cpd
1-methylnicotinamide : A pyridinium ion comprising nicotinamide having a methyl group at the 1-position. It is a metabolite of nicotinamide which was initially considered to be biologically inactive but has emerged as an anti-thrombotic and anti-inflammatory agent.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "MNA, however, did not affect venous thrombosis." | 1.34 | 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. ( Adamus, J; Bartus, M; Buczko, W; Chlopicki, S; Gebicki, J; Lomnicka, M; Mogielnicki, A; Swies, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, WP | 1 |
| Li, D | 1 |
| Lun, YZ | 1 |
| Gong, XJ | 1 |
| Sun, SX | 1 |
| Guo, M | 1 |
| Jing, LX | 1 |
| Zhang, LB | 1 |
| Xiao, FC | 1 |
| Zhou, SS | 1 |
| Chlopicki, S | 1 |
| Swies, J | 1 |
| Mogielnicki, A | 1 |
| Buczko, W | 1 |
| Bartus, M | 1 |
| Lomnicka, M | 1 |
| Adamus, J | 1 |
| Gebicki, J | 1 |
2 other studies available for n(1)-methylnicotinamide and Hypertension
| Article | Year |
|---|---|
Excess nicotinamide inhibits methylation-mediated degradation of catecholamines in normotensives and hypertensives.
Topics: Adult; Betaine; Blood Pressure; Catecholamines; Female; Homocysteine; Humans; Hypertension; Indicato | 2012 |
1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway.
Topics: Animals; Aorta; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Epoprostenol; Fibrinolytic Agents; Hy | 2007 |